Circulating tumor cells and survival in abiraterone‐ and enzalutamide‐treated patients with castration‐resistant prostate cancer

Circulating tumor cells and survival in abiraterone‐ and enzalutamide‐treated patients with... INTRODUCTIONWith nearly 410 000 diagnoses in Europe each year, prostate cancer remains the most commonly diagnosed cancer in men. Approximately 10‐20% of the patients will ultimately advance to lethal, metastatic castration‐resistant prostate cancer (mCRPC). A continued targeting of the androgen receptor (AR) signalling pathway has proven to be useful. This has led to the development and clinical validation of next generation androgen deprivation therapies, encompassing the CYP17 inhibitor abiraterone acetate, and the anti‐androgen enzalutamide. Due to shifts in reimbursement criteria, novel agents and guidelines in the treatment of CRPC, a heterogeneous landscape of patients exists with respect to the current clinical practice. Circulating tumor cell (CTC) enumeration using the CellSearch System demonstrated how CTCs are an accurate and independent predictor of survival in metastatic prostate cancer. Here, we reassessed the prognostic value of baseline CTC enumeration via a prospective, multicentre study in patients with mCRPC starting a new line of systemic therapy with either abiraterone acetate or enzalutamide. Next, we evaluated the association between survival and CTC changes relative to baseline CTC enumeration (ie, CTC dynamics) in patients who responded for at least 10‐12 weeks. Secondary objectives included the assessment of the relationship of CTCs with baseline prostate‐specific antigen (PSA), http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Prostate Wiley

Loading next page...
 
/lp/wiley/circulating-tumor-cells-and-survival-in-abiraterone-and-enzalutamide-8BgGbnzBR2
Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0270-4137
eISSN
1097-0045
D.O.I.
10.1002/pros.23488
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONWith nearly 410 000 diagnoses in Europe each year, prostate cancer remains the most commonly diagnosed cancer in men. Approximately 10‐20% of the patients will ultimately advance to lethal, metastatic castration‐resistant prostate cancer (mCRPC). A continued targeting of the androgen receptor (AR) signalling pathway has proven to be useful. This has led to the development and clinical validation of next generation androgen deprivation therapies, encompassing the CYP17 inhibitor abiraterone acetate, and the anti‐androgen enzalutamide. Due to shifts in reimbursement criteria, novel agents and guidelines in the treatment of CRPC, a heterogeneous landscape of patients exists with respect to the current clinical practice. Circulating tumor cell (CTC) enumeration using the CellSearch System demonstrated how CTCs are an accurate and independent predictor of survival in metastatic prostate cancer. Here, we reassessed the prognostic value of baseline CTC enumeration via a prospective, multicentre study in patients with mCRPC starting a new line of systemic therapy with either abiraterone acetate or enzalutamide. Next, we evaluated the association between survival and CTC changes relative to baseline CTC enumeration (ie, CTC dynamics) in patients who responded for at least 10‐12 weeks. Secondary objectives included the assessment of the relationship of CTCs with baseline prostate‐specific antigen (PSA),

Journal

The ProstateWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off